Audentes to build $109M gene therapy plant in North Carolina

Audentes Therapeutics will spend $109 million to build a gene therapy manufacturing plant in Sanford, N.C., the company said Feb. 18.  

Advertisement

Audentes, a subsidiary of Astellas Pharma, said the 135,000-square-foot plant will create 200 jobs. 

The first phase of construction will take place over the next 18 months, and the facility should be operational by next year, the drugmaker said. 

Pfizer, AveXis, bluebird bio and Eli Lilly all have or are also building manufacturing sites in North Carolina, according to BioPharma Dive. 

Read the full news release here. 

More articles on pharmacy:
Expect drug shortages by March if coronavirus continues to ravage China, expert warns
Sanofi, HHS to collaborate on coronavirus vaccine
Pharma execs blast Belcher Pharmaceuticals’ 600 percent drug price hike

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.